ATR and neoplasm: This tight window is critical, because preclinical studies showed that cells attempt to compensate for ATR inhibition by activating other repair kinases that act on Ser345 of CHK1 (by 2-4 hours).11 Five patients had appropriate tumor tissue in their paired biopsy samples.